Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trialYi‐Long Wu, Tony Mok, Seiji Niho et al.|The Lancet Oncology|2017Cited by 1.2k
Abstract CT031: A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumorsAlison M. Schram, Jayesh Desai, Wenlin Shao et al.|Cancer Research|2023Cited by 12